Analysts Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Price Target at $9.33

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has received a consensus recommendation of “Hold” from the five research firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $9.33.

ESPR has been the topic of several analyst reports. Bank of America cut shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, January 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Esperion Therapeutics in a report on Wednesday, April 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Monday, March 25th.

Esperion Therapeutics Stock Down 4.5 %

Shares of NASDAQ:ESPR opened at $1.90 on Friday. The business’s 50 day moving average is $2.40 and its 200 day moving average is $1.99. Esperion Therapeutics has a 12-month low of $0.70 and a 12-month high of $3.40. The stock has a market cap of $359.86 million, a price-to-earnings ratio of -0.90 and a beta of 0.84.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.03. The company had revenue of $32.25 million for the quarter, compared to the consensus estimate of $26.84 million. During the same quarter last year, the business posted ($0.76) earnings per share. As a group, equities research analysts expect that Esperion Therapeutics will post -0.68 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ESPR. Armistice Capital LLC purchased a new stake in shares of Esperion Therapeutics during the 4th quarter worth approximately $9,568,000. GSA Capital Partners LLP grew its holdings in Esperion Therapeutics by 159.1% during the third quarter. GSA Capital Partners LLP now owns 1,116,655 shares of the biopharmaceutical company’s stock valued at $1,094,000 after purchasing an additional 685,733 shares during the period. Monaco Asset Management SAM increased its position in Esperion Therapeutics by 68.5% in the third quarter. Monaco Asset Management SAM now owns 1,171,779 shares of the biopharmaceutical company’s stock worth $1,148,000 after buying an additional 476,477 shares during the last quarter. Wasatch Advisors LP raised its stake in shares of Esperion Therapeutics by 2.7% in the first quarter. Wasatch Advisors LP now owns 9,129,647 shares of the biopharmaceutical company’s stock valued at $24,467,000 after buying an additional 238,544 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Esperion Therapeutics by 120.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 413,704 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 225,767 shares during the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.